文献速递MDS 与骨髓增殖性肿瘤

起始剂量对芦可替尼治疗骨髓纤维化患者总生存的影响:基于AIFA监测注册的前瞻性真实世界研究

The impact of starting dose on overall survival in myelofibrosis patients treated with ruxolitinib: A prospective real-world study on AIFA monitoring registries.
PubMed 文献 · Br J Haematol · 2024-10-03

研究基于意大利药品管理局(AIFA)监测注册的前瞻性真实世界数据,纳入3494例接受芦可替尼治疗的骨髓纤维化患者,其中2337例(66.9%)以减量起始。基线特征平衡后,全剂量起始组中位总生存78.2个月(95%CI 65.9-89),减量起始组52.6个月(95%CI 49-56.6),p<0.001。

要点

  • 3494例骨髓纤维化患者中2337例(66.9%)以减量起始芦可替尼。
  • 减量起始者年龄更大、脾大更明显、IPSS风险更高、ECOG评分更差。
  • 基线平衡后全剂量起始组中位总生存78.2个月,减量起始组52.6个月(p<0.001)。

核心结论

  • 真实世界中多数骨髓纤维化患者以减量芦可替尼起始,减量起始与较差的总生存相关。

研究设计与样本

  • 前瞻性真实世界研究,基于意大利药品管理局(AIFA)监测注册,纳入3494例接受芦可替尼治疗的骨髓纤维化患者。

主要发现

  • 2337例(66.9%)以减量起始,减量起始者中位年龄70岁 vs 67岁,脾脏长径20 cm vs 19.1 cm,中位脾脏体积1064 cm3 vs 1016 cm3,IPSS风险比例30.9% vs 26.1%,ECOG评分大于1者14.3% vs 9.8%。
  • 基线特征平衡后,全剂量起始组中位总生存78.2个月(95%CI 65.9-89),减量起始组52.6个月(95%CI 49-56.6),p<0.001。
  • 亚组分析显示,在IPSS中危-2和高危患者中两组也存在明显差异。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Ruxolitinib is a JAK1/JAK2 inhibitor approved for the treatment of myelofibrosis (MF)-related splenomegaly or symptoms. The recommended starting dose depends on platelet count, regardless of haemoglobin level at baseline. In the recent years, an overall survival (OS) advantage was reported in patients treated with ruxolitinib compared with best available therapy. We analysed a large Italian cohort of 3494 patients identified by Agenzia Italiana del Farmaco (AIFA) monitoring registries. Of them, 2337 (66.9%) started at reduced dose: these patients were older (median age 70 vs. 67), with increased incidence of large splenomegaly (longitudinal diameter 20 vs. 19.1 cm, median volume 1064 cm3 vs. 1016 cm3), with higher IPSS risk (30.9% vs. 26.1%), and worse ECOG score (more than 1 in 14.3% vs. 9.8%). After balancing for baseline characteristics, Kaplan-Meier analysis showed a median OS of 78.2 months (95% CI 65.9-89) for patients who started at full dose and 52.6 (95% CI 49-56.6) months for patients who started with reduced dose (p < 0.001). Group analysis also showed a substantial difference in patients with intermediate-2 and high IPSS risk. The majority of MF patients in real-world analysis started with a reduced dose of ruxolitinib, which is associated with less favourable outcomes.

来源:Br J Haematol,查看原文。版权归原作者所有。

引用

  1. Breccia M, Celant S, Palandri F, et al. The impact of starting dose on overall survival in myelofibrosis patients treated with ruxolitinib: A prospective real-world study on AIFA monitoring registries. Br J Haematol. 2024. PMID: 39363576. doi:10.1111/bjh.19812

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。